Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Tevogen Bio Holdings Inc.

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company’s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations.

HMP Partners

TEVOGEN BIO

As we celebrate Ally O’Connor's two year anniversary with TEVOGEN BIO as Laboratory Operations Lead, we recognize the talent, dedication, and leadership she has brought to Team Tevogen!

"Ally is the epitome of professionalism, scientific excellence and know-how. When standing on a hospital unit waiting to treat my patient, hers was the face I wanted to see." - Dolores Grosso, Clinical Development Lead

"Tevogen is very proud of how quickly TVGN 489, its lead product candidate has moved from concept to reality. Without question, Ally is one of the people who contributed most to making that happen." - Neal Flomenberg, Chief Scientific Officer

#purposedriven #leadership #creativity #optimism #respect #equality

Our team has a combined 250+ years of diversified experience across the entire life sciences ecosystem, including pharmaceuticals, hospitals, insurance, education, and government. With vast experience in drug development, launching products globally, and commercialization spanning various therapeutic areas, our team has the agility of a start-up and the experience of an established corporation.

tevogen.com/about

Ryan Saadi, MD, MPH  |  Neal Flomenberg  |  Sadiq Khan
Dolores Grosso  |  Stephen Chen  |  Jeffrey Feike, MPH
Kirti Desai  |  Himanshu Patel  |  Judy Akhtar, DDS

#biotech #leadership #diversityandinclusion #celltherapy #oncology #neurology #virology #businessacumen

Killer T cells are white blood cells that play a vital role in the immune system’s defense against diseases, including cancer and viruses. Most CTLs, including those selected and expanded using the ExacTcell platform, express T cell receptors (TCRs) that can recognize and react against foreign antigenic peptides of infected or malignant cells presented in conjunction with an HLA molecule. CTLs can induce diseased cells to undergo programmed cell death by releasing their cytolytic granules, which produces pores in the target cell’s membrane and triggers apoptosis in the target cell. 

tevogen.com/technology

#biotech #tcells #innovation #celltherapy #oncology #neurology #virology

Our commercial scale ready first generation manufacturing process already yields a highly efficient ratio of doses per cell donor. We anticipate that our second generation, featuring Tevogen's exclusive TCR-T process, will substantially boost the quantity of doses generated.

tevogen.com/technology/

#biotech #tcells #innovation #celltherapy #oncology #neurology #virology #healthequality #unicornstartup

We believe that sustainable business success cannot be achieved unless the success contributes to societal prosperity. Affordability and commercial success must coexist.

Ryan Saadi, MD, MPH  |  Susan Podlogar  |  Jeffrey Feike, MPH
Lindee Goh  |  Victor Sordillo

#biotech #leadership #boardofdirectors #innovation #celltherapy #oncology #neurology #virology #businessacumen #unicornstartup

We are immensely grateful for the contributions made by Hogan Lovells in support of TEVOGEN BIO! Thank you to the many members of the Hogan Lovells team who have been collaborating with Tevogen Bio since our inception!

"Ashley Boyle has been a great addition to team Tevogen! Joining us with a strong background in Cell Therapy manufacturing her specialized technical skills have made her a valuable team member in driving Tevogen’s goals. She brings a structured and organizational approach to tackling projects and has helped to make great strides in process development. Looking forward to what the next year will bring her." - Ally O’Connor

TEVOGEN.COM

#purposedriven #healthequity #core  #curiosity #optimism #respect #equality

We are pleased to welcome Victor Sordillo, renowned global safety management expert, to our Board of Directors! 

Sordillo joins TEVOGEN BIO’s Board of Directors, alongside existing board members Curtis Patton, Ph.D., Susan Podlogar, M.B.A., Jeffrey Feike, M.P.H, Lindee Goh, Ph.D., and CEO Ryan Saadi, M.D., M.P.H.

#biotech #leadership #innovation

"Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation" (https://lnkd.in/gjuexnKA) 

A sincere thank you to Team Tevogen for all of your hard work leading up to this occasion!

Happy Fourth of July from TEVOGEN BIO! Wishing everyone a memorable day filled with celebration and gratitude. 🎆  

#independenceday #fourthofjuly #happyfourth 

TEVOGEN.COM

	Dec '21	Dec '22	Dec '23
net income	-15.60M -	4.41M 128.26%	-67.33K 101.53%
depreciation and amortization	9.38K -	230.82K 2,361.59%
deferred income tax
stock based compensation	582.41K -	4.58M 686.17%
change in working capital	-1.25M -	737.69K 159.07%	897.62K 21.68%
accounts receivables
inventory
accounts payables	-1.09M -	171.08K 115.66%	931.95K 444.75%
other working capital	-571.78K -	566.61K 199.10%	-34.33K 106.06%
other non cash items	10.98M -	8.32M 24.24%	256.03K 96.92%
net cash provided by operating activities	-5.27M -	-215.40K 95.92%	-1.38M 538.99%
investments in property plant and equipment	-109.73K -	-479.04K 336.58%
acquisitions net
purchases of investments	-351.90M -		-67.50K -
sales maturities of investments			342.98M -
other investing activites			342.92M -
net cash used for investing activites	-109.73K -		342.92M -
debt repayment	-12.50M -		-1.32M -
common stock issued	352.96M -
common stock repurchased			-342.98M -
dividends paid
other financing activites
net cash used provided by financing activities	12.50M -		-341.66M -
effect of forex changes on cash
net change in cash	7.12M -	-215.40K 103.03%	-120.35K 44.13%
cash at beginning of period	3.84K -	344.58K 8,878.14%	129.19K 62.51%
cash at end of period	7.12M -	129.19K 98.19%	8.84K 93.16%
operating cash flow	-5.27M -	-215.40K 95.92%	-1.38M 538.99%
capital expenditure	-109.73K -	-479.04K 336.58%
free cash flow	-5.38M -	-694.44K 87.10%	-1.38M 98.20%

COM:TEVOGEN

Tevogen Bio

Last Close

1.42

21/11 21:00

Market Cap

115.31M

Beta: -

Volume Today

4.15M

Avg: -

Preview